Different Doses of Belantamab Mafodotin

Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Class Refractory Multiple Myeloma

What's the purpose of the trial?

This phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and/or does not respond to treatment (or that has not responded to previous treatment) (refractory).

Trial status

Accepting patients

Phase
Phase 2
Enrollment
62
Last Updated
4 months ago
Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Belantamab Mafodotin

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Group I: Low Dose Belantamab Mafodotin

Accepting patients

Group II: Low Dose and High Dose Belantamab Mafodotin

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.